Fuzionaire Inc. has established a collaborative research agreement with McGill University to leverage the company's proprietary alkali metal catalyst platform in creating novel heterocyclic, biologically active, silicon-containing scaffolds and new silicon-based drug candidates.
Seagen Inc. and University of Minnesota have synthesized compounds and their antibody-drug conjugates (ADCs) comprising humanized monoclonal antibody (MAb) bound to Toll-like receptor 7 (TLR7) or TLR8 agonists through linker reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has patented cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has disclosed pyrimidines or pyridines acting as adenosine receptor antagonists reported to be useful for the treatment of cancer.
Accutar Biotechnology Inc. has identified sulfonamides acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer.
There is still a percentage of patients with multiple myeloma (MM) who do not respond to initial therapy, and they are considered as refractory MM patients. There is a need for novel biomarkers of treatment response in refractory MM.
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others.
RSS
